1
Robert P Lenk, Anthony G Durning, Robert J Klimchak, Joel Portnoff, Michelle L Tomsho: Method for size separation of particles. The Liposome Company, Kenneth B Rubin, Rosanne Goodman, September 7, 1999: US05948441 (69 worldwide citation)

Tangential flow filtration is used in the size separation of particles, such as liposomes and lipid particles. These particles may be passed through a tangential flow filtration device of any pore size desired. Tangential flow filter systems of various pore sizes may be used sequentially to obtain p ...


2
Paul R Meers, Charles Pak, Shaukat Ali, Andrew Janoff, J Craig Franklin, Ravi K Erukulla, Donna Cabral Lilly: Peptide-lipid conjugates. The Liposome Company, Rosanne Goodman, July 11, 2000: US06087325 (52 worldwide citation)

Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat ma ...


3
Lawrence D Mayer, Marcel B Bally, Pieter R Cullis, Richard S Ginsberg, George N Mitilenes: Liposomal antineoplastic agent compositions. The Liposome Company, Rosanne Goodman, Kenneth B Rubin, August 18, 1998: US05795589 (46 worldwide citation)

A method for encapsulation of antineoplastic agents in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes may be made by a process that loads the drug by an active mechanism using a transmembrane ion gradient, preferably a tranamembrane pH gradient. Using this technique, tra ...


4
Diane Harris Boschelli, Annette Marian Doherty, Ali Fattaey, David William Fry, Susanne Andrea Trumpp Kallmeyer, Zhipei Wu, Ellen Myra Dobrusin, Mark Robert Barvian: Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation. Warner Lambert Company, Charles W Ashbrook, Rosanne Goodman, December 24, 2002: US06498163 (43 worldwide citation)

This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferative disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2-(amino and thio)pyrido[2,3-d]pyrimidines and 2,4-diaminopyrimidines that are potent inh ...


5
Mircea C Popescu, Alan L Weiner, Marie S Recine, Andrew S Janoff, Leonard Estis, Lynn D Keyes, Carl R Alving: Potentiation of immune responses with liposomal adjuvants. The Liposome Company, Kenneth B Rubin, Rosanne Goodman, July 18, 2000: US06090406 (40 worldwide citation)

A high integrity liposome comprising at least one stabile lipid and at least one peptide-like therapeutic agent associated with said liposome, adapted for parenteral administration to an animal, including a human, and method according to manufacture and use. Immunizing dosage forms comprising a lipo ...


6
Alexander James Bridges: Irreversible inhibitors of tyrosine kinases. Warner Lambert Company, Charles W Ashbrook, Rosanne Goodman, May 13, 2003: US06562818 (40 worldwide citation)

The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyros ...


7
Lawrence T Boni, Andrew S Janoff, Sharma R Minchey, Walter R Perkins, Christine E Swenson, Patrick L Ahl, Thomas S Davis: Pharmaceutical compositions containing interdigitation-fusion liposomes and gels. The Liposome Company, Rosanne Goodman, July 11, 2000: US06086851 (36 worldwide citation)

This invention provides a composition containing a sized liposome comprising a lipid and an inducer; the sized liposome has a diameter of at most about 1 micron and the inducer is present in an amount effective to induce interdigitation-fusion of the sized liposome. Also provided herein are interdig ...


8
Andrew S Janoff, Pieter R Cullis, Marcel B Bally, Michael W Fountain, Richard S Ginsberg, Michael J Hope, Thomas D Madden, Hugh P Schieren, Regina L Jablonski: Methods of dehydrating, storing and rehydrating liposomes. The Liposome Company, Kenneth B Rubin, Rosanne Goodman, July 13, 1999: US05922350 (35 worldwide citation)

Dehydrated liposomes are prepared by drying liposome preparations under reduced pressure in the presence of one or more protective sugars, e.g., the disaccharides trehalose and sucrose. Preferably, the protective sugars are present at both the inside and outside surfaces of the liposome membranes. F ...


9
Mircea C Popescu, Alan L Weiner, Marie S Recine, Andrew S Janoff, Leonard Estis, Lynn D Keyes, Carl R Alving: Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use. The Liposome Company, Kenneth Rubin, Rosanne Goodman, June 29, 1999: US05916588 (32 worldwide citation)

A high integrity liposome comprising at least one stabile lipid and at least one peptide-like therapeutic agent associated with the liposome, adapted for parenteral administration to an animal, including a human, and method according to manufacture and use.


10
Ted C K Lee, Michael E Hrinda: Factor VIII formulations in high ionic strength media. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, Rosanne Goodman, Martin F Savitzky, February 25, 1997: US05605884 (31 worldwide citation)

Stable, highly purified Factor VIII protein formulations are provided in high ionic strength media which comprises: sodium chloride, potassium chloride or mixtures thereof; calcium chloride; and histidine as the buffering agent.